A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Keywords
toxicity
therapeutic use
80 and over
therapy
Adult
adverse effects
B-Cell
Chronic
B-Lymphocytes
Diffuse
Cohort Studies
blood
Diarrhea
drug effects
drug therapy
Female
Imidazoles
France
Hematoma
Hematology
Humans
Large B-Cell
Local
Leukemia
London
Lymphocytic
Male
Mantle-Cell
pathology
Neoplasm Recurrence
Lymphoma
Medicine
Patients
Pyrimidines
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
antagonists & inhibitors
Aged
Middle Aged